

# Cyclopeptides for treating amyloid diseases and their comorbidities

The main amyloid self-assembly and toxicity of A $\beta$ ,  $\alpha$ -synuclein and IAPP (or amylin) are linked to the pathogenesis of Alzheimer's (AD), Parkinson's disease (PD) and type 2 diabetes (T2D). These diseases are major health problems worldwide and have interconnected molecular mechanisms, partly through so-called "cross-seeding" of their amyloid proteins; this may link their pathologies and result in comorbidities and further complications in their treatment.




## Multi-site & multi-target inhibition plus aggregate remodeling

Here, we present MAACs (multifunctional anti-amyloid cyclopeptides), with lead compound 2i, representing the first-in-class small cyclic peptide with potent and multifunctional inhibition of amyloid self-assembly and cross-seeding between AD, T2D, and PD proteins, along with drug-like and diagnostic properties.

- 01 Strong binding to A $\beta$ 42 (AD), IAPP (T2D) and  $\alpha$ Syn (PD)
- 02 Act at nanomolar to low micromolar concentrations, small (~700 Da) and cheap to synthesize
- 03 Effective BBB crossing in cell models and highly resistant to proteolytic degradation
- 04 Highly soluble, non-amyloidogenic, and non-toxic up to concentrations far above those required for function

Amyloid diseases, cross-talk, & comorbidities



Copyright: A. Kapurniotu (2025)

IP RIGHTS

EP Priority Application

2025

## CHALLENGE

Amyloid diseases involve complex, disordered proteins that are difficult to target. Current inhibitors (antibodies, small molecules, peptides) have drawbacks such as low stability, low specificity, poor blood-brain barrier (BBB) permeability, and high production costs. Only a few controversial treatments are available, and no early diagnostic tests exist for amyloid formation.

## INNOVATION

A new class of drugs called Multifunctional Anti-Amyloid Cyclopeptides (MAACs), focusing on short, cyclized hexapeptides were developed. These peptides are designed to mimic key AD, T2D, and PD amyloid protein contact points, ensuring high affinity and specificity for these amyloid proteins. The lead MAAC (termed 2i) can inhibit the self-assembly (aggregation) of each of these proteins into toxic forms and to block cross-seeding between these proteins, which otherwise may accelerate disease progression and comorbidity. Moreover, MAACs are able to remodel or disassemble toxic amyloid oligomers and fibrils into non-toxic forms.

01 Basic principles observed · 02 Technology concept formulated · 03 Experimental proof of concept · 04 Technology validated in lab · 05 Technology validated in relevant environment · 06 Technology demonstrated in relevant environment · 07 System prototype demonstrated in operational environment · 08 System complete and qualified

TRL 08

TRL 07

TRL 06

TRL 05

TRL 04

TRL 03

TRL 02

TRL 01

Technology Readiness Level (TRL)



BayPAT

Innovation from Research & Science – BayPAT markets inventions on behalf of the Bavarian universities and universities of applied sciences.

An invention of Technical University of Munich



As one of the largest technology transfer offices in Germany, BayPAT evaluates and commercializes innovations from 28 research institutions. With our extensive experience and expertise in patenting and licensing technologies and our comprehensive range of services, we are your partner of choice. For more information visit [www.baypat.de](http://www.baypat.de)

Bayerische Patentallianz GmbH  
Dr. Nicola Hoesch  
nhoesch@baypat.de  
+49 (0)89 5480177-29  
Prinzregentenstr. 52  
80538 München

